Oruka Therapeutics (ORKA) vs. Its Peers Critical Review

Oruka Therapeutics (NASDAQ:ORKA) is one of 35 publicly-traded companies in the “Diagnostic substances” industry, but how does it compare to its peers? We will compare Oruka Therapeutics to similar companies based on the strength of its dividends, valuation, profitability, institutional ownership, risk, analyst recommendations and earnings.

Volatility & Risk

Oruka Therapeutics has a beta of 0.89, suggesting that its stock price is 11% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ peers have a beta of 1.25, suggesting that their average stock price is 25% more volatile than the S&P 500.

Valuation and Earnings

This table compares Oruka Therapeutics and its peers top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Oruka Therapeutics	N/A	-$5.34 million	-4.95
Oruka Therapeutics Competitors	$625.33 million	$7.82 million	-39.91

Oruka Therapeutics’ peers have higher revenue and earnings than Oruka Therapeutics. Oruka Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Analyst Ratings

This is a summary of recent recommendations for Oruka Therapeutics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Oruka Therapeutics	0	0	6	2	3.25
Oruka Therapeutics Competitors	856	801	1340	23	2.18

Oruka Therapeutics currently has a consensus target price of $43.17, suggesting a potential upside of 45.34%. As a group, “Diagnostic substances” companies have a potential upside of 37.99%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Oruka Therapeutics is more favorable than its peers.

Insider and Institutional Ownership

56.4% of Oruka Therapeutics shares are owned by institutional investors. Comparatively, 47.3% of shares of all “Diagnostic substances” companies are owned by institutional investors. 30.9% of Oruka Therapeutics shares are owned by insiders. Comparatively, 12.7% of shares of all “Diagnostic substances” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Oruka Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Oruka Therapeutics	N/A	-20.18%	-19.51%
Oruka Therapeutics Competitors	-456.55%	-21.40%	-14.61%

Summary

Oruka Therapeutics beats its peers on 9 of the 13 factors compared.

Oruka Therapeutics Company Profile

ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.